PD-1指导一种抑制瘤的新陈代谢程序,限制糖解和抑制T细胞淋巴瘤中AP-1的活动
Tim Wartewig1,2,3, Jay Daniels4,5, Miriam Schulz1,2
1TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.
Nature cancer
|September 18, 2023
概括
免疫检查点PD-1 (编程细胞死亡蛋白1) 通常通过限制能量生产来抑制T细胞淋巴瘤. 它的无活化增加了促进癌症的ACLY活性,提供了一个新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 由PDCD1编码的免疫检查点受体PD-1 (编程细胞死亡蛋白1),在T细胞中起到瘤抑制作用.
- 在T细胞非霍奇金淋巴瘤 (T-NHLs) 中,PDCD1经常被禁用,特别是在晚期,与预后不佳相关.
- 通过PD-1信号抑制T-NHL的精确机制在很大程度上仍未定义.
研究的目的:
- 阐明T细胞恶性瘤中PD-1信号传递的瘤抑制机制.
- 研究PD-1在T-NHLs中调节细胞代谢和转录因子中的作用.
- 确定PDCD1突变T-NHLs中的潜在治疗漏洞.
主要方法:
- 利用T-NHL的小鼠模型和分析初级患者样本.
- 研究了PD-1信号对细胞能量代谢,特别是糖解的影响.
- 研究了ATP酸酶 (ACLY) 的活性及其对包括AP-1在内的转录因子的下游影响.
- 评估了在PD-1缺乏的T-NHLs中药理学ACLY抑制的疗效.
主要成果:
- 发现PD-1信号限制了T细胞中的糖溶性能量产生和乙-CoA生成.
- PD-1的非激活促进ATP酸酶 (ACLY) 的活性,导致额外线粒体乙烯基-CoA的增加.
- 这种升高的乙-CoA推动了基因素乙化,增强了激活蛋白1 (AP-1) 转录因子的过活性.
- 对ACLY的药理抑制有效地破坏了异常的AP-1信号,并对PD-1缺乏的T-NHLs表现出毒性.
结论:
- PD-1 作为T细胞代谢和AP-1 转录因子活性的关键调节者.
- PDCD1突变在T-NHL中创造了基因型特定的漏洞,特别是通过ACLY-AP-1轴.
- 准ACLY代表了PD-1缺乏T细胞淋巴瘤的有前途的治疗策略.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K


